Company performance
Add to research
Current Price
as of Jul 11, 2025$4.14
P/E Ratio
N/A
Market Cap
$335.78M
Description
Add to research
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Metrics
Add to research
Overview
- HQGaithersburg, MD
- SectorHealth Technology
- IndustryBiotechnology
- TickerALT
- Price$4.14-5.91%
Trading Information
- Market cap$335.78M
- Float98.96%
- Average Daily Volume (1m)11,842,417
- Average Daily Volume (3m)5,564,258
- EPS-$1.25
Company
- Revenue$0.02M
- Rev growth (1yr)N/A
- Net income-$19.58M
- Gross margin-480.00%
- EBITDA margin-435,720.00%
- EBITDA-$21.79M
- EV$229.46M
- EV/Revenue11,472.89
- P/EN/A
- P/S15,638.38
- P/B2.27
- Debt/Equity1.12
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset